Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate.
Yasui, Masato; Hasegawa, Yoriko; Kawahara, Takashi; Kumano, Yohei; Miyoshi, Yasuhide; Matsubara, Nobuaki; Uemura, Hiroji.
Mol Clin Oncol
; 8(4): 592-594, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29541468
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone.
Experiencia inicial con acetato de abiraterona en pacientes con cáncer de próstata resistente a la castración
Abiraterone and increased survival in metastatic prostate cancer.
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.